Sympathoinhibitory pathway from caudal midline medulla to RVLM is independent of baroreceptor reflex pathway

Potas, J.R. and Dampney, R.A.L.
Department of Physiology and Institute for Biomedical Research, University of Sydney, NSW 2006, Australia

Running head: Sympathoinhibitory pathway from caudal midline medulla

Name and address for correspondence:
Prof R.A.L. Dampney
Department of Physiology, F13
The University of Sydney
NSW 2006
Australia
Tel: +61 -2-93514603
Fax: +61 -2-93516470
Email: rogerd@physiol.usyd.edu.au
Abstract

Glutamate stimulation of the caudal midline medulla (CMM) causes profound sympathoinhibition, due to GABAergic inhibition of presympathetic neurons in the rostral ventrolateral medulla (RVLM). We investigated whether the sympathoinhibitory pathway from CMM to RVLM, like the central baroreceptor reflex pathway, includes a glutamatergic synapse in the caudal ventrolateral medulla (CVLM). In pentobarbitone-anesthetised rats, the RVLM on one side was inhibited by a muscimol microinjection. Then, the response evoked by glutamate microinjections into the CMM or by baroreceptor stimulation was determined before and after (1) microinjection of the GABA receptor antagonist bicuculline into the RVLM on the other side, or (2) microinjections of the glutamate receptor antagonist kynurenate bilaterally into the CVLM. Bicuculline in the RVLM greatly reduced both CMM- and baroreceptor-evoked sympathoinhibition. Compared with the effect of vehicle solution, kynurenate in the CVLM greatly reduced baroreceptor-evoked sympathoinhibition, whereas its effect on CMM-evoked sympathoinhibition was not different to that of the vehicle solution. These findings indicate that the output pathway from CMM sympathoinhibitory neurons, unlike the baroreceptor and other reflex sympathoinhibitory pathways, does not include a glutamatergic synapse in the CVLM.

Key words: glutamatergic neurotransmission, caudal ventrolateral medulla, sympathoexcitatory neurons, central cardiovascular pathways
INTRODUCTION

Microinjection of neuroexcitatory amino acids into a discrete region within the caudal midline medulla (CMM) of the rabbit or rat causes a profound fall in arterial blood pressure, heart rate and sympathetic activity (3, 10, 28). In both species, this region is located in the ventral part of the CMM, at the rostrocaudal level corresponding to the middle third of the inferior olive (3,10, 28). In the rat, the CMM depressor region extends rostrocaudally for approximately 1.5 mm (10,28), and is centered on the level corresponding to the level 12.8 mm posterior to bregma, according to the atlas of Paxinos and Watson (20).

Inhibition of neurons or blockade of synaptic transmission within the CMM depressor region does not alter resting arterial pressure or sympathetic activity (3, 11), nor does it affect the cardiovascular reflex effects evoked by stimulation of arterial baroreceptors and cardiopulmonary receptors (11). Thus, the CMM depressor region does not appear to have a critical role in regulating the tonic level of arterial pressure or sympathetic activity. On the other hand, there is evidence that this CMM region may mediate depressor and sympathoinhibitory responses arising from supramedullary regions in the brain. For example, there is anatomical and electrophysiological evidence that neurons in the CMM receive descending inputs from the depressor region in the ventrolateral part of the midbrain periaqueductal grey (10, 23, 29), and it has been suggested that the acute sympathoinhibition that is evoked in severe haemorrhage or as part of other behavioural responses is mediated, at least in part, via this pathway (7, 11).

The output pathway via which stimulation of CMM neurons leads to profound sympathoinhibition has not been determined, although it has been shown in the rabbit that it includes a GABAergic synapse in the rostral ventrolateral medulla (RVLM) as a critical component (4). Consistent with this, Verberne et al. (28) showed that electrical or glutamate stimulation of the CMM in the rat inhibited the ongoing activity of RVLM presympathetic neurons. It is well known that RVLM presympathetic neurons are also inhibited via GABAergic synapses in response to stimulation of a variety of peripheral receptors, including arterial baroreceptors, cardiopulmonary receptors, and other vagally-innervated receptors (13,
The central pathway mediating the reflex sympathoinhibition evoked by excitation of these receptors also includes a glutamatergic synapse in the CVLM (9, 13, 27). Furthermore, it has recently been shown that the depressor response evoked by stimulation of afferent fibres within the greater splanchnic nerve is also mediated via a glutamatergic synapse in the CVLM (21).

These previous observations therefore raise the possibility that the inhibitory pathway from the CMM to the RVLM presympathetic neurons includes, like the central pathways subserving sympathoinhibition arising from arterial baroreceptors and a wide range of other visceral receptors, a glutamatergic synapse in the CVLM. The primary aim of this study was to test this hypothesis. In addition, as a first step, we have confirmed that in the rat, as in the rabbit (4), GABAergic transmission in the RVLM is crucial for CMM-evoked sympathoinhibition.
METHODS

**General procedures.** All experiments and procedures were performed on male Sprague-Dawley rats, and complied with the guidelines of the National Health and Medical Research Council of Australia and of the American Physiological Society. Each animal was anesthetised initially by exposure to a gas mixture of 5% halothane (Fluothane; Zeneca, Macclesfield, UK) and 30% oxygen in a container, following which halothane anesthesia was continued via a mask (1.5-3% in 30% oxygen) while cannulations were performed. The right femoral artery and vein were cannulated for the measurement of arterial pressure and the administration of drugs, respectively. The trachea was cannulated and all animals were then artificially ventilated with 1.5% halothane in 30% oxygen. The rat was then placed in a stereotaxic frame with the nose positioned at 3.0 mm below the interaural axis. The halothane ventilation was then replaced by intravenous anesthesia with sodium pentobarbitone (Nembutal; Boehringer Ingelheim; bolus injection initially of 45 mg/kg followed by continuous infusion at the rate of 15-20 mg/kg/hr. Inspiratory oxygen levels were maintained in the range 39-41%, and expired carbon dioxide levels were maintained in the range 3.5-4.5%. The remaining surgery (exposure of the medulla and renal nerve) was then performed under pentobarbitone infusion. The adequacy of the level of anesthesia was ensured by the lack of withdrawal reflexes to toe pinch. Core temperature was maintained at 36.5-37.2°C with a servocontrolled heating pad. Mean arterial pressure (MAP) and heart rate (HR) signals were derived from the arterial pressure signal by means of MacLab software (Chart v 4.0).

**Renal sympathetic nerve recording.** Renal sympathetic nerve activity (RSNA) was recorded from the left renal nerve. Following exposure and isolation, the renal nerve was placed on bipolar recording electrodes and covered with mineral oil. The signal was passed through a band-pass filter (20-750 Hz) and displayed and monitored on a cathode ray oscilloscope and audio amplifier. The filtered nerve signal was recorded on a Maclab recording system, rectified and integrated (resetting every 2.5 seconds). At the end of each experiment, lignocaine was
administered to the proximal end of the renal nerve, and the remaining signal was taken as the background noise level, and was thus subtracted from the level of RSNA recorded during the experiment.

**Stimulation of baroreceptors.** Arterial baroreceptors were stimulated by raising arterial pressure with an intravenous injection of phenylephrine (5-10µg in 0.05-0.10 ml saline). The dose of phenylephrine was chosen so as to produce an increase in MAP of 50-70 mmHg, and the gain of the sympathoinhibitory component of the reflex was calculated as the change in RSNA (measured as a percentage of the pre-stimulus baseline level) divided by the increase in MAP (in mmHg).

**Intramedullary microinjections.** Microinjections into the caudal medulla were made using a glass micropipette held with a micromanipulator. Injections were made by pressure, and the volume measured by observing the movement of the meniscus in the micropipette, using a dissecting microscope. Rostrocaudal, mediolateral and dorsoventral co-ordinates of the tip of the micropipette were referred to the calamus scriptorius. Microinjections of glutamate (50 mM, 50 nl) were made into the CMM in the midline, 1.5 mm rostral and 1.7 mm ventral to calamus scriptorius. These co-ordinates were selected because preliminary experiments established that glutamate microinjections at these co-ordinates consistently evoked a significant depressor response (i.e. decrease in MAP > 20 mmHg). In the rare cases where a glutamate microinjection into this CMM site failed to evoke a significant depressor and sympathoinhibitory response, the experiment was discontinued. Bilateral microinjections of kynurenate (27 mM,150 nl) were placed into either caudal or rostral subregions of the CVLM (CVLMc and CVLMr respectively). Microinjections into CVLMc were placed 0.5 mm rostral, 1.8 mm lateral and 2.3 mm ventral, and microinjections into CVLMr were placed at 1.5 mm rostral, 1.8 mm lateral and 2.1 mm ventral to calamus scriptorius. Again, preliminary experiments established that glutamate microinjections at these co-ordinates consistently evoked a significant depressor response (i.e. decrease in MAP > 30 mmHg).
Microinjections of muscimol (10 mM, 150 nl) and/or bicuculline (2 mM, 150 nl) were made into the pressor region in the RVLM, which was identified as the site at which a microinjections of glutamate (50 mM, 50 nl) evoked a pressor response of at least 20 mmHg. Usually, less than three penetrations were required to identify the RVLM pressor region on each side. The co-ordinates of the RVLM pressor region were usually at 2.3 mm rostral, 1.8 mm lateral and 2.1 mm ventral to calamus scriptorius. In most experiments, fluorescent-labelled microspheres were added to the injectate to enable histological examination of injection sites.

Experimental procedure. The basic experimental strategy was to test the effect of blockade of GABAergic neurotransmission in the RVLM, or of glutamate neurotransmission in the CVLM, on the sympathoinhibitory response evoked from the CMM as well as the reflex sympathoinhibitory response evoked by baroreceptor stimulation. However, bilateral blockade of GABA receptors in the RVLM, or of glutamate receptors in the CVLM, results in large increases in baseline MAP and RSNA (4, 17, 18). Therefore, to avoid this problem, a microinjection of muscimol, a long-lasting GABA receptor agonist (8), was first made into the RVLM on the left side in all experiments. Subsequently, in the first series of experiments, the effects on RSNA of stimulation of the CMM (by glutamate microinjection) and of stimulation of arterial baroreceptors (by raising MAP with phenylephrine injection) were tested before and after unilateral injection of the GABA receptor antagonist bicuculline into the RVLM on the other (right) side. In the second series of experiments, the effects on RSNA of stimulation of the CMM and of stimulation of arterial baroreceptors were tested before and after bilateral injections of kynurenate into the CVLM.

The time frame for the sequence of microinjections was as follows. Following microinjection of muscimol into the left RVLM, there was a waiting period of 7-15 min after which a control microinjection of glutamate was made into the CMM. Following the CMM-evoked response, when the cardiovascular variables had stabilised, there was a further waiting period of approximately 2 min, after which the baroreceptor reflex response was evoked. There was then a further waiting period of 10-15 min, after which bicuculline was injected into the right RVLM, or kynurenate injected bilaterally into the CVLM. When the cardiovascular
variables had stabilized following these injections, there was a further waiting period of approximately 5 min, after which a microinjection of glutamate was again made into the CMM. Finally, following the CMM-evoked response, there was a further waiting period of approximately 2 min after which the baroreceptor reflex response was again evoked. In control experiments, the procedures were the same, except that the vehicle solution (artificial cerebrospinal fluid, 144 mM NaCl, 1.2 mM CaCl₂, 2.8 mM KCl, 0.9 mM MgCl₂) was microinjected instead of bicuculline into the RVLM (first series of experiments), or instead of kynurenate into the CVLM (second series of experiments).

Finally, the effects of CMM and baroreceptor stimulation on RSNA were also measured in a separate group of animals in which no prior injection of muscimol was first made into the RVLM on one side.

**Histology.** At the end of the experiment, intracardiac perfusion of 500 ml of 0.9% saline, followed by 500 ml of 0.1 M phosphate buffer of pH 7.4 containing 4% paraformaldehyde was carried out. Brains were then removed and placed in 30% sucrose solution for several days at 4°C, after which 50-µm-thick sections were cut on a freezing microtome and mounted on to glass slides. Two adjacent series were collected at 250 µm intervals. Prior to being coverslipped, one series was stained for Nissl bodies. Brain sections were examined under the fluorescence microscope to confirm the location of injections into the medulla.

**Data analysis.** The baseline values for MAP, HR and RSNA were measured as the average values for each of these variables over the 12.5 sec period prior to the stimulus (i.e. CMM stimulation with glutamate, or baroreceptor stimulation via the phenylephrine-induced increase in MAP). The change in RSNA evoked by each stimulus was measured at the percentage maximum change in the integrated RSNA (averaged over successive 5-sec periods following each stimulus) relative to the pre-stimulus baseline level. Comparisons of responses evoked by each stimulus in the same animal before and after either blockade of GABAergic neurotransmission in the RVLM or glutamatergic neurotransmission in the CVLM were made.
using a paired t-test. Comparisons of responses in different groups of animals were made using an unpaired t-test. A P value of <0.05 was taken to indicate a statistically significant difference. All values are expressed as mean ± SE.
RESULTS

Effects of unilateral injection of muscimol into the RVLM on responses evoked by CMM and baroreceptor stimulation. In one group of 5 intact rats, the effects of glutamate microinjections into the CMM and of baroreceptor stimulation were tested before any other procedures were performed. The baseline levels of MAP and HR in this group of animals were 104±6 mmHg and 340±16 bpm, respectively. Glutamate microinjections (2.5 nmol) into the CMM in these rats consistently evoked large decreases in MAP, HR and RSNA (Table 1, Fig. 1). Baroreceptor stimulation (via a phenylephrine-induced increase in MAP) also resulted in a reflex bradycardia, and a profound reflex sympathoinhibition (Table 1).

As explained above in the Methods (see Experimental procedure) in all the other series of experiments the long-lasting GABA receptor agonist muscimol (8) was first injected into the RVLM on one side, in order to prevent the very large increases in baseline MAP that occurs following bilateral blockade of GABA receptors in the RVLM or of glutamate receptors in the CVLM. Before unilateral injection of muscimol into the left RVLM, the baseline levels of MAP and HR in all these experiments (n=32 in total) were 98 ± 2 mmHg and 321 ± 6 bpm. Following unilateral muscimol injection, the baseline levels of MAP and HR decreased significantly to 77 ± 2 mmHg (p<0.01) and 310 ± 5 bpm (p<0.05), respectively, and the baseline level of RSNA decreased significantly to 79 ± 3% (p< 0.01) of the original baseline level. Subsequently, glutamate microinjection into the CMM consistently evoked small decreases in MAP and HR but a large decrease in RSNA (Table 1). The depressor and bradycardic responses evoked by CMM stimulation in rats with unilateral inactivation of the RVLM were significantly less than these responses in the intact group (Table 1). On the other hand, the magnitudes of the renal sympathoinhibitory responses were not significantly different in the two cases (Table 1), although the duration of the sympathoinhibitory response (33 ± 3 sec) in the group with unilateral inactivation of the RVLM was significantly less than the duration of this response in the intact group (58 ± 6 sec, p<0.01). Although unilateral microinjections of muscimol into the left RVLM reduced the magnitude of the reflex bradycardia
and renal sympathoinhibition associated with phenylephrine-induced increases in MAP, these reductions were not significant when compared to the intact group (Table 1).

The effects of microinjection of bicuculline into the right RVLM on CMM- and baroreceptor-evoked sympathoinhibition. Subsequent to unilateral microinjection of muscimol into the left RVLM, microinjection of the vehicle solution into the right RVLM had no significant effect on the baseline levels of MAP, HR or RSNA (Table 2), nor on the magnitude of the sympathoinhibitory response evoked by glutamate stimulation of the CMM or the gain of the baroreceptor-sympathetic reflex (Fig. 2). Following microinjection of bicuculline into the right RVLM, the baseline level of RSNA was greatly increased (Table 2). There was also an increase in the baseline level of MAP, although this just failed to achieve statistical significance ($P = 0.059$). The CMM- and baroreceptor-evoked sympathoinhibitory responses were greatly reduced following bicuculline injection (Figs. 2, 3). When expressed as a percentage of the response before microinjection of bicuculline into the RVLM, the CMM-evoked sympathoinhibitory response and the baroreceptor-sympathetic reflex gain were reduced by $71 \pm 3\%$ and $72 \pm 12\%$, respectively.

The effects of microinjections of kynurenate into the CVLM on CMM and baroreceptor-evoked sympathoinhibition. Subsequent to unilateral microinjection of muscimol in the left RVLM, bilateral microinjection of the vehicle solution into the CVLM had no significant effect on the baseline levels of MAP, HR and RSNA (Table 2), but did result in a moderate but significant decrease in the magnitudes of both the CMM-evoked and baroreceptor evoked sympathoinhibitory responses (Fig. 4). When expressed as a percentage of their respective control responses before vehicle injections into the CVLM, these sympathoinhibitory responses were reduced by $33 \pm 12\%$ and $33 \pm 13\%$, respectively.

As described in the Methods, bilateral injections of kynurenate were made into either a more rostral or more caudal level of the CVLM, at 0.8 and 1.8 mm, respectively, caudal to the RVLM. This was done because sympathoinhibitory neurons in the CVLM appear to be distributed over a considerable rostrocaudal distance (5). Furthermore, there is evidence that
baroreceptor interneurons in the CVLM are concentrated in its more rostral portion (5) so that it was thought possible that the effect of kynurenate injections on CMM-evoked sympathoinhibition may differ according to the rostrocaudal level of the injection. There was, however, no significant difference in the effects of kynurenate injections on the CMM and baroreceptor-evoked sympathoinhibition, with respect to their rostrocaudal location in the CVLM, and so the results from these two groups of experiments were pooled.

Following bilateral microinjection of kynurenate into the CVLM, there was no significant change in the baseline levels of MAP and HR, but the baseline level of RSNA was significantly increased with respect to the baseline level before kynurenate injections (Table 2), although it was not significantly changed with respect to the original baseline level (p > 0.25). The sympathoinhibitory response evoked by glutamate stimulation of the CMM was reduced to a moderate but significant extent, but that evoked by baroreceptor stimulation was reduced to a much greater extent (Figs. 4, 5). When expressed as a percentage of their respective control responses before kynurenate injections into the CVLM, the CMM-evoked sympathoinhibitory response was reduced by 24 ± 12%, whereas the baroreceptor-sympathetic reflex gain was reduced by 76 ± 5%. The moderate reduction in the CMM-evoked sympathoinhibitory response following injections of kynurenate into the CVLM was not significantly different from that which occurred following injections of the vehicle, whereas in the same experiments the baroreceptor-evoked sympathoinhibitory response was reduced to a much greater extent following injections of kynurenate as compared with the vehicle solution (P < 0.01).

**Location of injection sites in the CMM, CVLM and RVLM.** Histological examination showed that the injection sites in the CMM depressor region were located in the midline, at the level corresponding most closely to the level 12.80 mm posterior to bregma, according to the atlas of Paxinos and Watson (20). In the RVLM the injection sites were located just ventral to the nucleus ambiguus, at the level just caudal to the caudal pole of the facial nucleus (i.e. corresponding most closely to the levels 11.80 or 11.96 mm posterior to bregma, (20)). Injection sites in the rostral and caudal subregions of CVLM were also located ventral to the nucleus ambiguus, but at levels which corresponded most closely to the levels 12.8 and 13.8
mm posterior to bregma, respectively (20). Examples of injection sites in the CMM, RVLM, and rostral and caudal subregions of CVLM are shown in Figs. 6A,B.
DISCUSSION

The results of this study indicate that in the rat, as in the rabbit, the powerful sympathoinhibition that is evoked by stimulation of neurons in the CMM is mediated via GABAergic inhibition of RVLM sympathoexcitatory neurons, as is the case for baroreceptor reflex sympathoinhibition. The main new finding, however, is that unlike the reflex sympathoinhibition arising from baroreceptor stimulation, sympathoinhibition evoked by glutamate stimulation of the CMM did not appear to be affected by blockade of ionotropic glutamate receptors in the CVLM. This finding indicates that, in contrast to the central pathways mediating reflex sympathoinhibition arising from stimulation of baroreceptors and many other peripheral receptors, the sympathoinhibitory pathway from the CMM to the RVLM does not include a glutamatergic synapse within the CVLM. The physiological implications of this finding are discussed below, after considering some methodological issues.

Methodological considerations. Apart from the first series of experiments in which the effects of glutamate stimulation of the CMM was measured, in all other experiments a microinjection of the long-lasting GABA receptor agonist muscimol (8) was first made unilaterally into the RVLM. The purpose of this was to inactivate the RVLM on one side, so that subsequently when bicuculline was injected into the RVLM on the other side, or kynurenate injected into the CVLM on both sides, the baseline arterial pressure and sympathetic activity would not increase to the same extent as is known to occur when RVLM neurons on both sides are disinhibited, following either bilateral blockade of GABA receptors in the RVLM or of glutamate receptors in the CVLM (14, 17, 18). We have previously shown that the inhibitory effects of muscimol in the RVLM last for at least 3 hr (12). The inhibitory effects of muscimol in the RVLM therefore would have persisted for the entire duration of the experiment, since all experimental procedures were completed within approximately one hour following the injection of muscimol.
Unilateral injection of muscimol into the RVLM did reduce the baseline level of MAP, but did not significantly affect the magnitude of the sympathoinhibition evoked by glutamate stimulation of the CMM, and resulted in only a small (but not statistically significant) decrease in the magnitude of the baroreceptor reflex sympathoinhibition evoked by a phenylephrine-induced increase in MAP. At the same time, unilateral inhibition of the RVLM did significantly reduce the magnitude of the depressor and bradycardic responses to CMM stimulation. This indicates that unilateral inhibition of the RVLM had non-uniform effects on the degree of CMM-evoked inhibition of the sympathetic outflows to the heart and different vascular beds. The reason for this non-uniformity is not clear, but one possibility is that, in comparison to renal sympathetic preganglionic neurons, the responsiveness of sympathetic preganglionic neurons regulating other vascular beds is much more dependent on bilateral inputs from the RVLM. Further studies are needed to answer this question.

The basic experimental strategy in this study was to compare, in the same experiments, the effects of blockade of GABA receptors in the RVLM or of glutamate receptors in the CVLM on CMM-evoked sympathoinhibition and baroreceptor reflex sympathoinhibition. Each experiment therefore served as its own control, since it is well established that baroreceptor reflex sympathoinhibition is dependent upon GABA receptors in the RVLM and glutamate receptors in the CVLM (15, 25). Furthermore, separate series of control experiments were performed to determine the effect of vehicle injection alone on the magnitude of the evoked responses.

Following muscimol microinjection into the RVLM on one side in combination with bicuculline injection into the RVLM on the other side, the baseline level of RSNA was greatly increased (to 245% of the original baseline level, as measured before any intramedullary microinjections were made). Thus, it could be argued that the firing rate of presympathetic neurons in the RVLM on the side where bicuculline was injected may have increased to such an extent that these neurons were not capable of being inhibited by an input originating from the CMM, whether is was mediated by GABA receptors or any other receptor. In a previous study, however, we showed that the profound sympathoinhibition evoked by CMM stimulation is unaffected even under conditions in which disinhibition of RVLM neurons occurs in
response to baroreceptor unloading (4). In that study, as in the present study, the change in RSNA evoked by CMM stimulation was measured relative to the baseline level of RSNA immediately before the stimulation was applied. Thus, this previous observation indicates that the reduction in the magnitude of the CMM-evoked decrease in RSNA that we observed following bicuculline injection into the RVLM is unlikely to be due simply to the increased baseline level of activity of RVLM presympathetic neurons, or to the method used to measure the degree of evoked sympathoinhibition. Furthermore, there is direct electrophysiological evidence in the rat that the large majority of RVLM presympathetic neurons are profoundly inhibited by stimulation of the CMM (28). Our findings are therefore entirely consistent with this study (28), and in addition indicate that in the rat, as in the rabbit (4), the CMM-evoked inhibition of RVLM presympathetic neurons is likely to be mediated by GABA receptors.

In contrast to the effect of bicuculline injection into the RVLM, bilateral injections of kynurenate into the CVLM had no apparent effect on CMM-evoked sympathoinhibition. Although there was a moderate reduction (of approximately 25%) in the magnitude of the evoked sympathoinhibition following kynurenate microinjections into the CVLM compared to the control response, a reduction of similar magnitude was also observed following bilateral injections of vehicle solution into the CVLM. Thus, this modest reduction in the magnitude of the CMM-evoked sympathoinhibition is likely to be due to non-specific effects of the injection itself, such as mechanical distortion of the tissue, rather than to specific blockade of CVLM glutamate receptors.

In contrast to the CMM-evoked response, when the baroreceptor reflex sympathoinhibitory response was evoked in the same experiments, this was reduced to a much greater extent (by approximately 75%) following microinjection of kynurenate, but not vehicle solution into the CVLM. The effect of kynurenate injections in reducing the baroreceptor reflex sympathoinhibition is expected, because glutamate receptors in the CVLM are known to be a crucial component of the baroreceptor-sympathetic reflex pathway (for review see 6). Thus, our finding that kynurenate in the CVLM had no apparent effect on the CMM-evoked sympathoinhibition indicates that this pathway is not mediated by glutamate receptors in the CVLM.
As mentioned above, the kynurenate microinjections into the CVLM did not completely block the baroreceptor reflex sympathoinhibition. The volume of kynurenate injected (150 nl) was relatively large, so as to maximise the degree of glutamate receptor blockade in the CVLM. The would explain why kynurenate injections into the rostral and caudal portions of the CVLM had similar effects on baroreceptor reflex sympathoinhibition, even though baroreceptor interneurons are believed to be more concentrated in the rostral part of CVLM (5). Thus, because of the large injection volume, kynurenate injected into the caudal portion of the CVLM may have spread to the more rostral portion of CVLM. Despite this, it is still possible that there was incomplete blockade of glutamate receptors in the CVLM, including some that mediate the baroreceptor reflex. Consistent with this, the increase in baseline RSNA that occurred following kynurenate microinjections into the CVLM was modest. Alternatively, the residual baroreceptor reflex sympathoinhibition could be mediated by other pathways, such as a descending pathway which inhibits sympathetic activity at a spinal level (16). Regardless of this, however, the results of our experiments indicate that the sympathoinhibitory pathway from the CMM to the RVLM is quite separate from the sympathoinhibitory pathway activated by stimulation of arterial baroreceptors. It is also separate from the sympathoinhibitory pathways activated by stimulation of a variety of other visceral receptors (e.g. cardiopulmonary receptors, and receptors innervated by the superior laryngeal nerve or greater splanchnic nerve), all of which also include a glutamatergic synapse in the CVLM as well as a GABAergic synapse in the RVLM (9, 13, 21, 24, 25, 27).

What are the possible central pathways mediating CMM-evoked sympathoinhibition?

Anatomical studies using anterograde and retrograde transport have shown that there is a projection from the midline medulla to the RVLM, but this appears to arise mainly from neurons located more rostral than the CMM sympathoinhibitory region (2, 19, 22, 26, 30). Thus, the available evidence suggests that CMM-evoked sympathoinhibition is unlikely to be mediated by a direct monosynaptic projection to RVLM presympathetic neurons. It therefore seems more likely that the sympathoinhibitory pathway from the CMM is polysynaptic, with direct or indirect connections with other medullary or supramedullary nuclei (such as the nucleus of the
solitary tract or the Kölliker-Fuse nucleus in the pons) which are major sources of afferent inputs to the RVLM (6). Further studies are needed to identify this pathway.

**Perspectives**

As has been shown previously (3, 28), and confirmed in this study, glutamate stimulation of the CMM region produces profound sympathoinhibition, similar to that evoked from the CVLM depressor region. This therefore raises the important question as to the physiological function of the CMM sympathoinhibitory neurons. The results of the present study indicate that the sympathoinhibitory pathway from the CMM to the RVLM is quite separate from reflex sympathoinhibitory pathways activated by stimulation of arterial baroreceptors and a variety of other visceral receptors. This therefore implies that the CMM neurons do not play an important role in mediating reflex responses arising from these receptors. Consistent with this, Henderson et al. (11) found that the reflex responses evoked by stimulation of arterial baroreceptors or cardiopulmonary receptors were not affected by inactivation of neurons in the CMM. On the other hand, there is anatomical and electrophysiological evidence that neurons in the CMM receive descending inputs from the ventrolateral part of the midbrain periaqueductal grey (10, 23, 29), which is believed to evoke sympathoinhibition as part of a more generalized passive behavioral response to various environmental stressors (1). Furthermore, Henderson et al. (11) have recently proposed that, whereas the CVLM mediates reflex sympathoinhibitory responses evoked from arterial baroreceptors and other peripheral receptors, the CMM mediates sympathoinhibitory responses that are part of more complex behavioural responses. The finding of the present study that the central pathways mediating CMM-evoked and baroreflex sympathoinhibition are quite separate, until their ultimate convergence on presympathetic neurons in the RVLM, is consistent with this hypothesis.
ACKNOWLEDGMENTS

We gratefully acknowledge the assistance of Dr Marco Fontes, Dr Jaimie Polson and Ms Suzanne Killinger. The study was supported by the National Health and Medical Research Council of Australia.
REFERENCES


FIGURE LEGENDS

Figure 1: Example of the cardiovascular response evoked by microinjection of glutamate (Glu) (2.5nmol) into the caudal midline medulla (CMM). RSNA, renal sympathetic nerve activity.

Figure 2. Grouped results showing effects of GABA-receptor blockade in the right RVLM on sympathoinhibition evoked by CMM or baroreceptor stimulation. In all experiments, muscimol (1.5nmol) was first injected into the left RVLM. The changes in renal sympathetic activity (RSNA) evoked by microinjection of glutamate (2.5 nmol) into the CMM (A) and also the magnitude of the baroreceptor-sympathetic reflex gain (B) were then determined before and after microinjection of either bicuculline (300pmol; n=5) or vehicle solution (n=4) into the right RVLM. * indicates p<0.05 vs. control response; ** indicates p<0.01 vs. control response. In each case, the change in RSNA is shown as the percentage change with respect to the baseline level immediately before the CMM or baroreflex response was evoked.

Figure 3. Example of effects on renal sympathetic nerve activity (RSNA) evoked by microinjection of glutamate (Glu) (2.5nmol) into the caudal midline medulla (CMM) and by a phenylephrine (PE)-induced increase in arterial pressure, before (A) and after (B) unilateral microinjection of bicuculline (300 pmol) into the RVLM on the right side, in one experiment. (A microinjection of muscimol (1.5 nmol) had first been made into the RVLM on the left side). The scale for the raw RSNA signal is the same in both A and B.
Figure 4. Grouped results showing effects of glutamate-receptor blockade in the CVLM on sympathoinhibition evoked by CMM or baroreceptor stimulation. In all experiments, muscimol (1.5nmol) was first injected into the left RVLM. The changes in renal sympathetic activity (RSNA) evoked by microinjection of glutamate (2.5 nmol) into the CMM (A) and also the magnitude of the baroreceptor-sympathetic reflex gain (B) were then determined before and after bilateral microinjections of either kynurenate (4 nmol; n=15) or vehicle solution (n=8) into the caudal ventrolateral medulla. * indicates p<0.05 vs. control response; ** indicates p<0.01 vs. control response. In each case, the change in RSNA is shown as the percentage change with respect to the baseline level immediately before the CMM or baroreflex response was evoked.

Figure 5. Example of effects on renal sympathetic nerve activity (RSNA) evoked by microinjection of glutamate (Glu) (2.5nmol) into the caudal midline medulla (CMM) and by a phenylephrine (PE)-induced increase in arterial pressure, before (A) and after (B) bilateral microinjections of of kynurenate (4 nmol) into the caudal ventrolateral medulla, in one experiment. (A microinjection of muscimol (1.5 nmol) had first been made into the RVLM on the left side).

Figure 6. Injection sites as determined by histological analysis in two experiments, drawn on to the standard sections of the medulla oblongata from the atlas of Paxinos and Watson (20). In both experiments, bilateral injections of kynurenate were made into the CVLM, at the level of the caudal (A) or rostral (B) parts of CVLM. The injection sites for muscimol into the left RVLM (upper panels) and for glutamate into the CMM (middle panels) are also shown.
Table 1. Effects on cardiovascular variables of CMM and baroreceptor stimulation under normal conditions and following unilateral inactivation of the RVLM

<table>
<thead>
<tr>
<th></th>
<th>Normal conditions (n=5)</th>
<th>Unilateral RVLM inactivation (n=32)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glutamate injection into CMM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔMAP (mmHg)</td>
<td>-39 ± 5</td>
<td>-9 ± 1**</td>
</tr>
<tr>
<td>ΔHR (bpm)</td>
<td>-33 ± 13</td>
<td>-9 ± 2**</td>
</tr>
<tr>
<td>ΔRSNA (% baseline)</td>
<td>-59 ± 7</td>
<td>-52 ± 4</td>
</tr>
<tr>
<td>Phenylephrine infusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔMAP (mmHg)</td>
<td>64 ± 2</td>
<td>67 ± 3</td>
</tr>
<tr>
<td>ΔHR (bpm)</td>
<td>-45 ± 10</td>
<td>-29 ± 3</td>
</tr>
<tr>
<td>ΔRSNA (% baseline)</td>
<td>-76 ± 4</td>
<td>-58 ± 4</td>
</tr>
</tbody>
</table>

Values are mean ± SE. MAP, mean arterial pressure; HR, heart rate; RSNA, renal sympathetic nerve activity. ** p<0.01 vs normal conditions.
Table 2. Baseline levels of MAP, HR and RSNA before and after injections of various compounds into the RVLM or CVLM.

<table>
<thead>
<tr>
<th></th>
<th>Injections into RVLM</th>
<th>Injections into CVLM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vehicle</td>
<td>Bicuculline</td>
</tr>
<tr>
<td></td>
<td>n=4</td>
<td>n=5</td>
</tr>
<tr>
<td>Before injection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>77 ± 3</td>
<td>72 ± 4</td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>325 ± 11</td>
<td>307 ± 17</td>
</tr>
<tr>
<td>RSNA (% original</td>
<td>76 ± 5</td>
<td>89 ± 7</td>
</tr>
<tr>
<td>baseline level)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>After injection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>79 ± 4</td>
<td>109 ± 14</td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>373 ± 27</td>
<td>344 ± 25</td>
</tr>
<tr>
<td>RSNA (% original</td>
<td>95 ± 10</td>
<td>245 ± 27**</td>
</tr>
<tr>
<td>baseline level)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Values are mean ± SE. MAP, mean arterial pressure; HR, heart rate; RSNA, renal sympathetic nerve activity. **p<0.01 vs before injection.
Figure 1.
Figure 2.

A CMM response

B Baroreflex response

ΔRSNA (% baseline)

Baroreflex gain (ΔRSNA/ΔMAP)
Figure 3.
Figure 4.
Figure 5.
Figure 6.